Floatz logo

PEGFILGRASTIM

Lymphocyte-Rich Classic Hodgkin Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Lymphocyte-Rich Classic Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
National Cancer Institute (NCI)
Phase 3BB
DACARBAZINE
National Cancer Institute (NCI)
Phase 3BB
Brentuximab Vedotin
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Nivolumab
National Cancer Institute (NCI)
Phase 3BB

View all 11 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

Chemotherapy-induced NeutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
neutropeniaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →